Abiopharma

Jiangsu Expressway Company Limited (the "Company") was incorporated in August 1992, registered capital of which is RMB 5,038 million at present, and it is principally engaged in the investment, construction, operation and management of some toll expressways within Jiangsu province. The Company core asset is the Jiangsu section of the Shanghai-Nanjing Expressway, and still has all or some equity interests of toll roads and bridges within Jiangsu province, including: the Shanghai-Nanjing section of G312, Xicheng Expressway, Guangjing Expressway, the Nanjing section of the Nanjing-Lianyungang Expressway, the Jiangsu section of the Sujiahang Expressway and Jiangyin Yangtze River Bridge, etc. The mileage of highways that the Company manages has already exceeded 700 km at present, and total assets are about RMB 25 billion. The Company becomes one of the largest asset-scale domestic listed companies in the trade.

Additional info from OTC:
Jiangsu Expressway Company Limited (the "Company") was incorporated in August 1992, registered capital of which is RMB 5,038 million at present, and it is principally engaged in the investment, construction, operation and management of some toll expressways within Jiangsu province. The Company core asset is the Jiangsu section of the Shanghai-Nanjing Expressway, and still has all or some equity interests of toll roads and bridges within Jiangsu province, including: the Shanghai-Nanjing section of G312, Xicheng Expressway, Guangjing Expressway, the Nanjing section of the Nanjing-Lianyungang Expressway, the Jiangsu section of the Sujiahang Expressway and Jiangyin Yangtze River Bridge, etc. The mileage of highways that the Company manages has already exceeded 700 km at present, and total assets are about RMB 25 billion. The Company becomes one of the largest asset-scale domestic listed companies in the trade.